Citigroup
MLTX icon

Citigroup’s MoonLake Immunotherapeutics MLTX Stock Holding History

Citigroup’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.4K Sell
1,358
-12,333
-90% -$224K ﹤0.01% 5112
2026
Q1 		$255K Buy
13,691
+12,781
+1,405% +$212K ﹤0.01% 3888
2025
Q4 		$12K Sell
910
-7,111
-89% -$83.9K ﹤0.01% 5005
2025
Q3 		$57.5K Buy
8,021
+5,050
+170% +$263K ﹤0.01% 4447
2025
Q2 		$140K Sell
2,971
-18,257
-86% -$744K ﹤0.01% 4245
2025
Q1 		$829K Buy
21,228
+20,016
+1,651% +$862K ﹤0.01% 3377
2024
Q4 		$65.6K Buy
+1,212
New +$61.9K ﹤0.01% 5003
2024
Q1 		– Sell
-2,297
Closed -$139K – 5776
2023
Q4 		$139K Buy
2,297
+2,265
+7,078% +$117K ﹤0.01% 4078
2023
Q3 		$1.82K Sell
32
-571
-95% -$31.5K ﹤0.01% 4986
2023
Q2 		$30.8K Sell
603
-76,673
-99% -$2.06M ﹤0.01% 4848
2023
Q1 		$1.65M Sell
77,276
-89,041
-54% -$1.5M ﹤0.01% 2150
2022
Q4 		$1.75M Buy
166,317
+7,230
+5% +$64.3K ﹤0.01% 2144
2022
Q3 		$1.27M Hold
159,087
– – ﹤0.01% 2526
2022
Q2 		$835K Buy
+159,087
New +$1,000K ﹤0.01% 2813

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citigroup's MLTX Position: Q2 2026 in Review

Citigroup reduced its MoonLake Immunotherapeutics (MLTX) stake by 90% in Q2 2026, selling an estimated $224K and leaving 1,358 shares worth $26.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5112.

Citigroup first reported a position in MLTX in Q2 2022 and has held it in 14 quarters since. The position peaked at $1.75M in Q4 2022. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Citigroup held 1,358 shares of MoonLake Immunotherapeutics worth $26.4K as of Q2 2026.
  • Citigroup sold 12,333 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $224K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5112 holding.
  • Citigroup first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 14 quarters since.
  • Citigroup's MoonLake Immunotherapeutics position peaked at $1.75M in Q4 2022.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.